Beyond Harmony begins: first patient dosed in Phase 3 ASD study
Neurotech International Limited (ASX: NTI) has dosed the first patient in its pivotal Phase 3 Beyond Harmony clinical study, formally commencing the trial of NTI164 in children with Autism Spectrum Disorder (ASD). The milestone advances NTI164 into pivotal Phase 3 clinical development and marks a significant step toward the company’s objective of regulatory registration and commercialisation of NTI164 as a potential treatment for the core symptoms of ASD.
Beyond Harmony is a national multi-centre, randomised, double-blind, placebo-controlled Phase 3 study spanning six sites across Australia, covering Victoria, Queensland, New South Wales, Tasmania, and Western Australia. Up to 200 patients are planned for enrolment under an adaptive trial design. Following recent media coverage of the trial, the company has received more than 300 enquiries from parents and caregivers seeking information about potential participation, providing confidence in its ability to recruit within the planned timeframe.
When big ASX news breaks, our subscribers know first
What is the Beyond Harmony study and why does it matter for investors?
A Phase 3 pivotal trial is the critical final stage of clinical testing required before a company can submit a therapy for regulatory approval. Unlike earlier-stage studies that primarily assess safety and early signals of efficacy, a Phase 3 trial is statistically powered to generate the definitive evidence regulators require to approve a new treatment. Beyond Harmony is designed specifically for that purpose, combining a rigorous placebo-controlled design with a patient population large enough to detect clinically meaningful effects.
Why ASD is a critical unmet medical need
No approved medications currently exist that effectively address the core behavioural symptoms of Autism Spectrum Disorder. There are no established medications available that effectively treat the core behavioural symptoms of ASD. This absence of approved therapies for core ASD symptoms represents a substantial unmet need and defines the market opportunity NTI164 is seeking to address.
The adaptive trial design explained
Beyond Harmony’s adaptive design is a scientific and operational strength of the study. Key features include:
- Pre-specified modifications are permitted based on interim analyses, allowing the trial to respond to emerging data without compromising integrity.
- The statistical and scientific validity of the study is maintained throughout any adaptations, as modifications are pre-planned rather than ad hoc.
- The design is aligned with contemporary regulatory expectations, supporting a more efficient path to a registration-quality dataset.
Building on HARMONY: the clinical foundation behind Phase 3
Beyond Harmony does not emerge from a standing start. It builds directly on the HARMONY Phase II/III study, a 54-patient, randomised, double-blind, placebo-controlled trial evaluating NTI164 in children aged 2 to 17 years with ASD. HARMONY generated clinically meaningful and statistically significant results across a range of validated measures, supported by an excellent safety profile.
The HARMONY data subsequently formed part of the clinical evidence submitted in Neurotech’s recently cleared Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The study has also been published in Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics, following independent peer review of the methodology, analysis, and findings. FDA IND clearance and peer-reviewed publication in a respected journal represent credible, regulatory-grade evidence, positioning NTI164 ahead of many clinical-stage programs entering Phase 3 without that foundation.
FDA IND clearance formally authorises the commencement of a US clinical development program and establishes a direct pathway toward potential future FDA registration, complementing the Australian Phase 3 data with a population pharmacokinetic study designed to support cross-jurisdictional regulatory alignment.
Executive Chairman, Mark Davies
“Dosing the first patient in Beyond Harmony is a significant milestone for Neurotech and marks the commencement of what is an important pivotal study for NTI164 in autism.
“We enter this Phase 3 program with a strong clinical foundation established through our previous HARMONY study, which demonstrated clinically meaningful and statistically significant benefits across multiple validated measures, together with an excellent safety profile.
“With the HARMONY clinical trial now published following independent peer review, we are pleased to advance NTI164 into Phase 3. Our focus is on successfully executing Beyond Harmony and progressing NTI164 toward regulatory registration as a new treatment option for children with ASD. Autism sufferers have a significant unmet therapeutic need with no established medication available that effectively treats autism’s core behavioural symptoms.”
NTI164 and the path to regulatory registration
NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation, and upstream biological mechanisms implicated in neurodevelopmental disorders. Successful execution of Beyond Harmony would support regulatory registration and commercialisation of NTI164 as a potential treatment for the core symptoms of ASD in children.
US patent protection for NTI164 extends the commercial case alongside the clinical program, with USPTO Notices of Allowance issued across two applications covering neuroinflammation reduction and ASD treatment, both expected to provide exclusivity through to 2042.
Neurotech’s broader clinical pipeline
Beyond ASD, Neurotech has completed and reported statistically significant and clinically meaningful results across several other paediatric neurological indications, reflecting the breadth of the company’s clinical program.
| Indication | Study Phase | Design | Status | Key Outcome |
|---|---|---|---|---|
| ASD (Beyond Harmony) | Phase 3 | Randomised, double-blind, placebo-controlled; adaptive design | Active — first patient dosed | Up to 200 patients; powered for regulatory registration |
| ASD (HARMONY) | Phase II/III | Randomised, double-blind, placebo-controlled | Completed and published | Clinically meaningful and statistically significant results; excellent safety profile; part of cleared US FDA IND application |
| PANDAS/PANS | Phase I/II | Clinical trial | Completed and reported | Statistically significant and clinically meaningful results |
| Rett Syndrome | Phase I/II | Clinical trial | Completed and reported | Statistically significant and clinically meaningful results |
| Spastic Cerebral Palsy | Phase I/II | Clinical trial | Human ethics committee clearance received | Trial clearance granted; yet to commence |
With all six sites initiated and the first patient now dosed, Neurotech’s near-term focus is on executing Beyond Harmony and progressing NTI164 toward regulatory registration as a potential new treatment option for children with ASD.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.